Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
307.35B
Market cap307.35B
Price-Earnings ratio
16.79
Price-Earnings ratio16.79
Dividend yield
2.68%
Dividend yield2.68%
Average volume
11.16M
Average volume11.16M
High today
$124.19
High today$124.19
Low today
$121.50
Low today$121.50
Open price
$122.20
Open price$122.20
Volume
9.66M
Volume9.66M
52 Week high
$124.19
52 Week high$124.19
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 307.35B, Merck(MRK) trades at $123.82. The stock has a price-to-earnings ratio of 16.79 and currently yields dividends of 2.7%.

As of 2026-02-23, Merck(MRK) stock has fluctuated between $121.50 and $124.19. The current price stands at $123.82, placing the stock +1.9% above today's low and -0.3% off the high.

The Merck(MRK)'s current trading volume is 9.66M, compared to an average daily volume of 11.16M.

In the last year, Merck(MRK) shares hit a 52-week high of $124.19 and a 52-week low of $73.31.

In the last year, Merck(MRK) shares hit a 52-week high of $124.19 and a 52-week low of $73.31.

MRK News

Simply Wall St 6h
Merck Restructures Human Health To Highlight Oncology And Post Keytruda Growth

Merck (NYSE:MRK) plans to split its Human Health business into two divisions: one for oncology and one for specialty, pharma, and infectious diseases. The rest...

Merck Restructures Human Health To Highlight Oncology And Post Keytruda Growth
Benzinga 11h
Merck's Strategic Shift Signals New Growth Horizons

Merck & Co. Inc. (NYSE:MRK) shares are up during Monday’s premarket session as the company is evolving its Human Health organization to enhance commercial execu...

Merck's Strategic Shift Signals New Growth Horizons
Barron's 12h
Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Feature Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff. In this article MRK SNY Merck’s blockbuster cancer treatment Keytruda...

Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Analyst ratings

60%

of 30 ratings
Buy
60%
Hold
40%
Sell
0%

More MRK News

TipRanks 13h
Merck announces new operating structure in Human Health business

Merck (MRK) announced changes in the structure of its Human Health organization. Merck is organizing its Human Health business into an Oncology Business Unit an...

TipRanks 14h
Merck plans to split human-health business into two divisions, WSJ says

Merck (MRK) is planning to split its human-health business into two divisions, one that will house its cancer drugs and the other will sell noncancer products,...

The Wall Street Journal 14h
Merck Creates Separate Cancer Business as Sales Pressure Looms

Keytruda is due to lose its U.S. patent protection in 2028. David Crosling/EPA-EFE/Shutterstock Merck MRK 0.33 %increase; green up pointing triangle is shaking...

Merck Creates Separate Cancer Business as Sales Pressure Looms
The Motley Fool 1d
Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades

The company might bend, but it won't break. Over the past year, Merck's (MRK +0.33%) shares have climbed by 46%. That seems a bit surprising. Last year, the co...

Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades
TipRanks 5d
‘An Important Potential New Option:’ Merck Stock Slides despite Successful RSV Trial

Drugmaker Merck & Company’s (MRK) shares edged lower in Thursday’s pre-market trading despite reporting positive results from its late-stage SMART clinical tria...

Simply Wall St 5d
Merck Mayo AI Partnership Aims To Sharpen Drug Discovery Decisions

Merck (NYSE:MRK) and Mayo Clinic announced a new research and development partnership focused on using artificial intelligence and multimodal clinical data for...

Merck Mayo AI Partnership Aims To Sharpen Drug Discovery Decisions
TipRanks 6d
Merck announces Health Canada approval of KEYTRUDA SC

Merck (MRK) announced that Health Canada has approved KEYTRUDA SC, a new subcutaneous formulation of pembrolizumab, Merck’s anti-PD-1 therapy. The approval is b...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.